SUBSCRIBE
SUBSCRIBE

Cystic fibrosis

Drug Development
Inside ReCode’s New-in-Class Approach to Treating Cystic Fibrosis
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
June 17, 2021
 · 
5 min read
 · 
Heather McKenzie
A patients story who suffered cystic fibrosis.
Drug Development
Cystic Fibrosis: One Patient’s Story, Current Treatments and Exciting New Therapies on the Horizon
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
May 10, 2021
 · 
13 min read
 · 
Chelsea Weidman Burke, M.S.
Load More
PRESS RELEASES
Genetown
Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis
March 6, 2024
 · 
4 min read
Business
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024
 · 
7 min read
BioCapital
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF
January 25, 2024
 · 
3 min read
Drug Development
Vast Therapeutics Announces Publication of Potential New Treatment for Non-tuberculosis Mycobacteria Infections
January 17, 2024
 · 
2 min read
Business
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
January 5, 2024
 · 
4 min read
FDA
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
January 4, 2024
 · 
5 min read
Genetown
Cystic Fibrosis Rescued by Reprogramming the Cell’s Secretory Machinery
January 3, 2024
 · 
3 min read
Genetown
Sionna Therapeutics to Present Updates on Clinical Progress in Cystic Fibrosis at 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
 · 
4 min read
Drug Development
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
November 29, 2023
 · 
10 min read
FDA
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
November 27, 2023
 · 
5 min read
Genetown
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
November 2, 2023
 · 
9 min read
Genetown
Tract Bio Announces Publication in American Journal of Respiratory and Critical Care Medicine Highlighting Stem Cell Variants Driving Lung Inflammation in Modulator-Treated Cystic Fibrosis Patients
November 1, 2023
 · 
3 min read
Business
Moligo Technologies and Nationwide Children’s Hospital Collaborate to Advance Cystic Fibrosis Research Using Ultrapure Long Single-Stranded DNA
October 24, 2023
 · 
3 min read
Business
ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders
October 4, 2023
 · 
4 min read
Business
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
September 26, 2023
 · 
5 min read
BioCapital
CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy
September 26, 2023
 · 
2 min read
Drug Development
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections
September 7, 2023
 · 
4 min read
Genetown
Porosome Therapeutics, Inc. Files Comprehensive Patent for New Generation of Treatments for Cystic Fibrosis and Other Diseases
August 21, 2023
 · 
5 min read
Genetown
Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective
July 25, 2023
 · 
2 min read
Drug Development
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase FormulationTopline data expected in July 2023
June 28, 2023
 · 
6 min read
Load More